Teva provides financial forecast – with a caveat

Teva Pharmaceutical Industries Ltd. provided analysts Friday with its projections for revenues and earnings in 2017, but included a caveat with its numbers. The generic drug giant said it expects revenues in the $23.8 billion to $24.5 billion range, and operating income of between $7.4 billion and $7.8 billion. Those numbers assume its Copaxone, the company’s branded multiple sclerosis drug, does not face generic competition in the United States thi s year. Teva expects sales of Copaxone, its top…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news